Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting

Therapeutics and Clinical Risk Management

Volumn 10, Issue 1, 2014, Pages 9-15

  Colombo, Giorgio L ^a,b   Castagna, Antonella ^c   Di Matteo, Sergio ^b   Galli, Laura ^c   Bruno, Giacomo ^b   Poli, Andrea ^c   Salpietro, Stefania ^c   Carbone, Alessia ^c   Lazzarin, Adriano ^c,d  

^a UNIVERSITY OF PAVIA   (Italy)

^b SAVE Studi Analisi Valutazioni Economiche   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

HAART; HIV; Multi tablet regimen; Pharmacoeconomics; Single tablet regimen

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; YOUNG ADULT;

EID: 84891110614     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S49428     Document Type: Article

References (31)

1. Mocroft A, Ledergerber B, Katlama C, et al; EuroSIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362(9377):22-29.
2. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. July 26, 2008;372(9635):293-299.
3. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010;376(9734):49-62.
4. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344(11):824-831.
5. National Committee on AIDS, Ministry of Health National Commission for the Fight Against AIDS. Linee Guida Italiane sull'utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1 [Italian guidelines on antiretroviral drugs and the diagnostic-clinical management of HIV patients]. 2012. Italian. Available at: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1793_allegato.pdf. Accessed September 15, 2013.
6. Nachega JB, Rosenkranz B, Pham PA. Twice-daily versus oncedaily antiretroviral therapy and coformulation strategies in HIV infected adults: benefits, risks, or burden? Patient Prefer Adherence. 2011;5:645-651.
7. Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials. 2002;3(5):371-378.
8. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36(3):808-816.
9. Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW. Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression. HIV Clin Trials. 2008;9(3):164-176.
10. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence. 2010;4: 115-125.
11. European Medicines Agency (EMA). Atripla [summar y of European public assessment report]. London: EMA; 2009 [updated October 3, 2012]. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000797/human_med_000657.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125. Accessed June 10, 2013.
12. Lombardy Region. Social and Health Care Plan. No 937/2010. Milan: Lombardy Region; 2010. Italian. Available at: http://www.sanita.egione.lombardia.it/shared/ccurl/956/366/DGRregole_e_allegati.zip. Accessed June 10, 2012.
13. Lombardy Region. Approvazione del documento avente peroggetto Percorso Diagnostico Terapeutico (PDT) per il paziente affetto da malattia HIV/AIDS [Therapeutic and diagnostic path (PDT) for the patient with HIV/AIDS disease]. Decree no 7485, August 5, 2011. Milan: Lombardy Region; 2012. Italian. Available at: http://www.sanita.regione.lombardia.it/cs/Satellite?c=Page&childpagename=DG_Sanita/Page/NormativaDetail&pagename=DG_SANWrapper&cid=1213275902673&keyid=3520. Accessed June 10, 2012.
14. Agenzia Italiana del Faramco [AIFA; Italian Drug Agency]. Negoziazione e rimborsabilitá [Negotiation and reimbursement; web page on the Internet]. Rome: AIFA; 2013. Italian. Available at: http://www.agenziafarmaco.gov.it/it/content/negoziazione-e-rimborsabilit%C3%A0. Accessed November 13, 2011.
15. Istat. Indice dei prezzi al consumo per le rivalutazioni monetarie [Consumer Price Index for inflation adjustments]. Roma: Istituto nazionale di statistica. Available from: http://www.istat.it/it/archivio/30440. Accessed November 7, 2013.
16. Liotta G, Caleo GM, Mancinelli S. Analysis of survival in HIV-infected subjects according to socio-economic resources in the HAART era. Ann Ig. 2008;20(2):95-104.
17. Moeremans K, Annemans L, Löthgren M, et al. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. Pharmacoeconomics. 2010;28 Suppl 1:107-128.
18. Colombo GL, Colangeli V, Di Biagio A, Di Matteo S, Viscoli C, Viale P. Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. Clinicoecon Outcomes Res. 2011;3:197-205.
19. Rizzardini G, Bonfanti P, Carenzi L, et al. Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy. Ther Clin Risk Manag. 2012;8:377-384.
20. Foglia E, Bonfanti P, Rizzardini G, et al. Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world. PLoS One. 2013;8(2):e57777.
21. Rizzardini G, Restelli U, Bonfanti P, et al. The cost of HIV disease in Northern Italy: the payer's perspective. J Acquir Immune Defic Syndr. 2011;57(3):211-217.
22. Rizzardini G, Restelli U, Bonfanti P, et al. Cost of human immunodeficiency virus infection in Italy, 2007-2009: effective and expensive, are the new drugs worthwhile? Clinicoecon Outcomes Res. 2012;4:245-252.
23. Simpson KN, Luo MP, Chumney E, Sun E, Brun S, Ashraf T. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials. 2004;5(5):294-304.
24. Colombo GL, Di Matteo S, Maggiolo F. Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen. Clinicoecon Outcomes Res. 2013;5:59-68.
25. Antinori A, Marcotullio S, Ammassari A, et al; Italian HIV Guidelines Working Group. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol. 2012;35(2):113-159.
26. D'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Patients. AIDS. 2000;14(5):499-507.
27. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21-30.
28. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181-1183.
29. Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009;50(5): 529-536.
30. Antinori A, Cozzi-Lepri A, Ammassari A, et al; AdICoNA Study Group. Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antivir Ther. 2004;9(2): 291-296.
31. Borghi C, Cicero AFG. Aderenza e persistenza in terapia. [Adherence and persistence in therapy]. Giornale Italiano di Farmacoeconomia e Farmaco Utilizzazione. 2008;1(2):5-13. Italian.